Study of D-CMG for older adults with new AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination called D-CMG for people aged 60–75 who have just been diagnosed with a type of leukemia (AML) and cannot have standard chemotherapy. The goal is to find a safe and effective dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old.
- You have been diagnosed with acute myeloid leukemia (AML), but not a subtype called APL or certain low-risk gene changes.
- You have not received any prior treatment for your leukemia.
- You cannot take standard chemotherapy because of your age, other health problems, or personal choice.
- Your kidney and liver function are within acceptable limits.
- You are able to care for yourself (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (venetoclax, chidamide, and azacitidine) followed by another combination (decitabine plus MAG) for older adults with untreated acute myeloid leukemia (AML) who cannot have standard chemotherapy. It aims to offer a gentler but effective treatment option.
This study compares two chemotherapy combinations for older adults newly diagnosed with acute myeloid leukemia (AML) that has certain gene changes (NPM1 or IDH1/IDH2). The goal is to see if the new combination works better and has fewer side effects than the standard one.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This trial aims to help doctors choose the best treatment for older adults with acute myeloid leukemia (AML) by using a special health assessment that looks at your overall well-being. The study will compare different treatment options based on this assessment, with the goal of improving outcomes and quality of life.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This Phase 2 trial tests a new combination treatment (the “CAV regimen”) for people with relapsed or refractory acute myeloid leukemia (AML). It may help your body control leukemia again, especially if prior standard intensive treatments were not enough or the leukemia came back.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.